Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 seralutinib inhalation study in pulmonary arterial hypertension
NL-OMON60842Phase 3Completed
- Sponsor
- GB002, Inc.
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Seralutinib + background PAH therapy with Placebo + background PAH therapy (2 arms). Primary endpoint: Change in six-minute walk distance. Started Mar 2024; status: completed.
02
Drugs
seralutinib
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NL-OMON60842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60842.